Press Room

    Back

    Press Release - August 13, 2008

    Sernova Corp.'s Diabetes Technology Featured at International Congress of the Transplantation Society and on CTV National News


    London, Ontario --August 13, 2008 - Sernova Corp. (TSX-V: SVA)

    Sernova Corp.'s Sertolin technology is being highlighted at the International Congress of The Transplantation Society (TTS) in Sydney, Australia this week, and was also featured on CTV's National News on Sunday night, with the message that Canadian innovation may be changing the face of diabetes forever.

    "Our cell replacement technology, Sertolin, could free insulin dependent (Type 1) diabetics from insulin injections forever," said Dr. David White, Principal Researcher for Sernova Corp. and presenter at the TTS international congress. "We are working to change what it means to be a diabetic, and we are doing it today."

    Dr. White's presentation at thecongress, and the CTV National News media coverage, both describe the development of Sernova'sinsulin replacement cellular therapy called Sertolin. A small medical device containing two types of mature porcine (pig) cells (islet and Sertoli cells) is implanted just beneath the skin of a Type 1 diabetic's abdomen.The cells produce insulin that is compatible with human insulin, thus reducing or eliminating the need for constant insulin injections. The Sertoli cells protect the islets from attack by the immune system, eliminating the need for anti-rejection drugs that cause significant side effects.

    "Sertolin is so important in the fight against diabetes," said Dr. White. "This is not just about insulin; it's about quality of life and reducing the life threatening complications that come along with this disease. Sertolin will make life easier for diabetics. I am proud to see Sernova's important work highlighted at the International Congress of The Transplantation Society in Sydney and featured on the CTV National News."

    "Dr. White's invitation to present our Sertolin data in Sydney shows the high degree of scientific interest in our work in the international scientific community,"commented Justin Leushner, President and CEO of Sernova Corp. "We are excited to share our story."

    To watch the CTV National News piece --please click on link below http://watch.ctv.ca/news/latest/controversial- research/#clip72928

    About Sernova Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

    For further information contact: Craig Gauld, Executive Vice President Tel: (519) 858-5126 info@sernova.com www.sernova.com

    THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE

    Back



    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs

    Link

    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance

    PDF

    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario

    Link

    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Publisher: StockInterview.com
    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Publisher: StockInterview.com
    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Publisher: StockInterview.com
    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News